Enfermedad tromboembólica venosa y edadResultados del Registro Informatizado de Enfermedad Tromboembólica (RIETE)

Resumo

Venous thromboembolic disease (VTE) includes pulmonary embolism (PE) and deep vein thrombosis (DVT). The incidence of VTE increases with age and recurrence, bleeding and mortality during treatment may differ in different age groups. Centenarians and very young patients are poorly represented in clinical trials with anticoagulant treatment, so we do not know the complications of the disease and treatment in these age groups. We used data from the RIETE registry to assess the clinical characteristics, risk factors and outcomes during anticoagulation in VTE patients aged ≥ 100 años and 10–24 years. Subsequently, the data have been analysed and two papers have been published, "Venous thromboembolism in centenarians" and "Venous thromboembolism in young adults". In summary, our study reveals that standard anticoagulation induced only minimal side effect, while the negative outcomes of VTE in centenarians remain extremely serious, since the risk of dying of PE outweigh the risk of bleeding. Therefore, our data support the use of full-dose anticoagulant therapy in this population. On the other hand, in most young patients with PE the clinical characteristics at baseline may hinder early diagnosis and stratification of PE. During anticoagulation, women had similar rates of VTE recurrences and major bleeding, but in men the risk for VTE recurrences far outweighed the risk for bleeding. These differences were likely not due gender itself since they disappeared after adjusting for potential confounders.